Sentien’s SBI-101 overcomes conventional cell therapy challenges and is designed to enable patients to benefit from the vast potential of MSCs.

By immobilizing allogeneic, bone marrow-derived MSCs in an extracorporeal device, SBI-101 mimics the natural environment of MSCs and enables sustained, dynamic delivery of anti-inflammatory and regenerative secreted factors directly into the patient’s bloodstream.

Sentien Product

Realizing the Therapeutic Promise of MSCs

Due to their broad acting, responsive and dynamic immunomodulatory properties, bone-marrow derived MSCs have shown significant therapeutic potential in numerous preclinical models of disease including acute kidney injury, myocardial infarction, type I diabetes mellitus, and graft-versus-host disease, among many others, which together share a common feature of underlying systemic inflammation. 

Benefits of MSCs

Easily acquired from healthy donors and cultured in the lab

Have shown no significant adverse reactions in human trials thus far

Contain anti-inflammatory and regenerative therapeutic activity

Straightforward isolation and expansion techniques

Overcoming Challenges of MSC Therapy

Although generally shown to be safe in human trials, MSC infusions have had limited efficacy in the clinic. Studies have demonstrated that shortly following direct injection or intravenous infusion methods, the vast majority of systemically administered MSCs are filtered out in the lungs and are undetectable in circulation within a few hours of administration. Given this rapid clearance, the limited exposure window may not be sufficient to elicit a therapeutic response.

SBI-101 solves these problems by reprogramming the blood in an extracorporeal device that mimics the natural environment of MSCs and maintains MSC viability for the duration of treatment. This design facilitates the natural function of MSCs in dynamically sensing and responding to inflammatory stimuli to restore balance to a dysregulated immune system.

Sentien has exclusively licensed IP from the Massachusetts Institute of Technology and Massachusetts General Hospital that broadly covers the use of MSCs in extracorporeal devices.

Key Advantages

Recreates the natural environment of MSCs

Extends period of MSC cell viability and immune cell interaction

Allows sensing of inflammatory mediators in blood

Promotes dynamically responsive secretion of MSC factors

Reprograms the immune system

Integrates into existing treatment modalities

Overcomes MSC dosage limitations

Enables monitoring of MSC activity during treatment

Duration of Therapeutic Activity